Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 23 - 81 |
| Updated: | 4/21/2016 |
| Start Date: | December 2003 |
| End Date: | May 2015 |
Imaging of neuroendocrine (NETs), such as carcinoids and pheochromocytomas (PHEOs), is
suboptimal, limiting curative treatment. The investigators wanted to explore the use of PET
and F-DOPA i.v. for the localization of these types of neoplasms. The investigators used a
similar protocol as they had used for PET (Positron emission tomography) or FDG
(Fludeoxyglucose) imaging in oncologic patients. F-DOPA, prepared according to United States
Pharmacopeia (USP) guidelines, was approved by the North Shore University Hospital Radiation
Safety Committee in 1989 and 1994 for the study of neurological diseases and used
uneventfully.
suboptimal, limiting curative treatment. The investigators wanted to explore the use of PET
and F-DOPA i.v. for the localization of these types of neoplasms. The investigators used a
similar protocol as they had used for PET (Positron emission tomography) or FDG
(Fludeoxyglucose) imaging in oncologic patients. F-DOPA, prepared according to United States
Pharmacopeia (USP) guidelines, was approved by the North Shore University Hospital Radiation
Safety Committee in 1989 and 1994 for the study of neurological diseases and used
uneventfully.
Background: Pre surgical conventional imaging of neuroendocrine tumors (NETs) with CT, MRI,
In-111 octreotide or 1-123-MIBG (metaiodobenzylguanidine) scintigraphy has limitations. This
pilot study tried to improve the localization of these tumors with F-18-F-DOPA PET scanning.
Methods: The investigators studied 22 patients, the majority referred with clinical
diagnosis of carcinoid (9) or NETs (9) and a few with pheochromocytoma/paraganglioma (3).
Carbidopa was administered prior to the F-DOPA injection in 12 patients. Comparison was made
with prior conventional imaging. The F-DOPA findings, read blindly to the findings of other
modalities, were compared with results of subsequent surgery (2), endoscopy (1), or a
long-term follow up of mean duration of 49 months (for 20 patients). Two subjects were lost
to follow-up.
In-111 octreotide or 1-123-MIBG (metaiodobenzylguanidine) scintigraphy has limitations. This
pilot study tried to improve the localization of these tumors with F-18-F-DOPA PET scanning.
Methods: The investigators studied 22 patients, the majority referred with clinical
diagnosis of carcinoid (9) or NETs (9) and a few with pheochromocytoma/paraganglioma (3).
Carbidopa was administered prior to the F-DOPA injection in 12 patients. Comparison was made
with prior conventional imaging. The F-DOPA findings, read blindly to the findings of other
modalities, were compared with results of subsequent surgery (2), endoscopy (1), or a
long-term follow up of mean duration of 49 months (for 20 patients). Two subjects were lost
to follow-up.
- Inclusion Criteria:
- 23 years of age and older
- Appropriate diagnosis by referring physician
- Exclusion Criteria:
- Less than 23 years of age
- Greater than 81 years of age
- Pregnancy
- Lactation
- Prior history of radiation treatment
- Chemotherapy or anti-tuberculosis medications.
We found this trial at
1
site
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
Click here to add this to my saved trials
